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ABSTRACT The 41`2 monoclonal antibody (mAb) has been shown to recognize a 120-kilodalton
glycoprotein expressed on the cell surface of human peripheral blood monocytes, activated (but not
resting) T or B cells, and T and B lymphoblastoid cell lines . In this report we show that 4F2 mAb
specifically binds to the surface of adherent human embryonic fibroblasts but fails to bind to normal
adult fibroblasts. Moreover, 4F2 antigen was expressed on sarcoma-derived or SV40-transformed
adult fibroblastic cells. Finally, addition of 4F2 mAb inhibited the growth of cultured HT-1080
fibrosarcoma cell line, but had no inhibitory effect on various embryonic and adult normal or
transformed fibroblasts.
Several cell surface antigens present at the cell surface of
human mononuclear cells have been recently defined by the
use of monoclonal antibodies (mAb§)' (1). Some of these
antigens are selectively expressed by T cell subsets with differ-
ent functional activities or by cells at different stages of
differentiation and/or maturation (2).
Although in some instances these surface antigens are se-
lectively expressed by cells of the lymphoid lineage, several
mAb§ appear to recognize surface structures that may be
expressed also by other cell types, including hemopoietic or
neural cells(l, 3, 4).
A useful cell model system that has been extensively ex-
ploited for chromosomal, genetic, and biochemical analysis is
represented by human fibroblasts of both embryonic and
postnatal origin. Although a largeamount ofdata are available
on biological and biochemical properties, lifespan, growth
rates, and functional patterns of embryonic and adult human
fibroblasts (5-13), no surface markers have been available up
till now that define different stages of fibroblastdifferentiation
or activation. Thus, we tested a battery of mAb§ on human
fibroblastic cells of both embryonic and adult origin. The
mAb§ were selected on the basis of their reactivity with cell
surface antigens expressed on mononuclear cells at different
I Abbreviations used in this paper:
￿
FCR, fibrin clot retraction;
mAb(§), monoclonal antibody(s); MEM, Eagle's minimum essential
medium.
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differentiation and/or maturation stages and known to play
a regulating role on different cell functions.
In the present report we show that the 4F2 mAb, which
recognizes a 120-kilodalton glycoprotein (14) expressed on
human peripheral blood monocytes, activated T or B cells,
and T and B lymphoblastoid cell lines (14-16), birds to the
cell surface of adherent fibroblasts of embryonic but not of
adult origin. Furthermore, 4F2 antigen was detected on sar-
coma-derived or SV40-transformed adult fibroblastic cells.
Finally, addition of 4F2 mAb prevented the growth of cul-
tured fibrosarcoma-derived HT-1080 cell line, but had no
inhibitory effect on proliferation ofa variety of embryonic or
adult normal and transformed fibroblasts.
MATERIALS AND METHODS
Cefl Lines:
￿
Cell lines designated "964 lung"and "964skin" werederived
from the same embryo (kindly provided by Dr. J. Pontén, Uppsala University,
Sweden); the cell lines WI-38 (7), IMR-90 (17), VA-13, MCR-5 (18), ICIG-7
(13), and ICIG-7-SV40, ICIG-8, ICIG-9 (the two latter derived from the same
embryo), and the cloned somatic human-mouse hybrid MRC-5 x CI ID (19)
were kindly provided by Dr. A. Macieira-Coelho (Institut de Cancérologie et
d'Immunologie, Villejuif, France). Embryonic cells were tested between the
10th and the 19th passage.
Adult cell lines designated AG-4151, AG-4353, AG-4445, and AG-4059
were purchased from the Human Genetic Mutant Cell Repository (Institute
for Medical Research, Camden, NJ). AJ cells were obtained from Dr. L.
Kopelovitch (Sloan-KetteringMemorial Cancer Center, NY)and NSand MVL
cells from Dr. M. Marell (Ghent University, Belgium). HGandHG-SV40were
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Cancer, Centre National de la Recherche Scientifique, Villejuif, France). Te-85
cellline was obtained from Dr. J. Rhim(National InstitutesofHealth, Bethesda,
MD)and HT-1080 andRD cell lines were purchased from the American Type
Culture Collection (Rockville, MD) . Mns (12), Glen, DUP/N, and DUP/A
were established in culture according to a previously described technique (12) .
Adult normal (HU-EYE) and SV40-transformed (HJ-EYE SV40) fibroblasts
from human neuroretina were obtained from Dr . A . Benedetto (Virology
Center, S. Camillo Hospital, Rome). Normal adult cells were tested between
the 4th and the 12th passage. All the cell lines were found to be free of
mycoplasma contamination . Cultures were maintained in Eagle's minimum
essential medium (MEM) supplemented with 10% fetal bovine serum and 16
,ug/ml gentamycin .
Immunofluorescence:
￿
Confluent cultures were trypsinized and the
cells were resuspended in complete growth medium and seeded onto sterile
glass coverslips layered on 60-mm Petri dishes filled with complete growth
medium . 48 h later, the coverslips were washed three times in MEM and
incubated at 4°C for 20 min with different mAbs (1 :100 dilution of ascitic
fluids in MEM) including 4172, 3AI (reacting with 85% human peripheral
blood T cells) (20), DI/12, 134/22, 9/22, and PTF (all directed against HLA-
DR molecules) (21, 22), and BT3/4 (which recognizes the HLA-DR-like DC 1
supertypic specificity) (22). After beingextensivelywashed in MEM, the cover-
slips were incubated with a fluorescein isothiocyanate-conjugated goat anti-
mouse Ig. After 20 min at 4°C, the coverslipswere washed threetimes inMEM
and mounted in 90% glycerol in PBS . Controls were performed by incubating
with the second reagent only.
Addition of 4172 mAb and Evaluation of Cell Spreading,
Fibrin Clot Retraction (FCR), and Growth Rates :
￿
To evaluate
the effect of 4172 mAb on cell spreading and FCR, confluent ICIG-7 and HT-
1080 cultureswere trypsinized, resuspendedin growth medium, and centrifuged
at 1,000 rpm for 10 min . The cell pellets were resuspended in Tyrode solution
with or without 4172mAb (1:100, 50 pl x 106 cells) and incubated at 4°C for
20 min .
Cell suspensions were then scored visually by indirect immunofluorescence
assays. The cell suspensions were then seeded onto plastic Petri dishes with or
without a fibrin gel layer (5 x 10' cells per 30-mm dish) or tested for FCR
according to previously described techniques (24, 25).
To evaluate the effect of 4172 mAb on the growth rate of 4172* cell lines,
confluent ICIG-7, ICIG-7-SV40, WI-38, VA-13, HG-SV40, TE-85, and HT-
1080 cells were trypinized and resuspended in MEM supplemented with 10%
heat-inactivated fetal bovine serum and 1:100 dilutions of4172 mAb or ascitic
fluid obtained by injection of the original myeloma (P3 x 63/Ag8) in the
syngenic mice (14). Cells were then seeded at 7 x 104 cells per Petri dish and
at daily intervals cells oftwo cultures in each group were recovered by trypsin-
ization and counted with an electronic Coulter counter. Medium with or
without 4172 mAb was substituted every 24 h .
RESULTS
In a preliminary screening, the embryonic ICIG-7 and the
adult MVL cell lines were tested for reactivity with the panel
ofmAbs indicated in Materials and Methods . None of the
mAbs analyzed reacted with adult or embryonic fibroblasts,
with the remarkable exception of the 4172 mAb which selec-
tively stained 100% of embryonic cells . (Fig. 1 A). To further
investigate the distribution pattern of4172 antigen expression
on human fibroblastic cells of different origins, several cell
lines derived from embryonic, adult, or malignant tissues
were tested by indirect immunofluorescence .
As shown in Table I, all the embryonic cell lines analyzed
bound 4172 mAb . No substantial difference in 4172 expression
was detected among cell lines derived either from different
embryonic tissues or from embryos ofdifferent ages. The two
SV40-transformed cell lines VA-13 and ICIG-7-SV40 were
4172-positive in a similar fashion as the nontransformed pa-
rental cell lines (WI-38 and ICIG-7).
We further analyzed the 4172 expression on a cloned somatic
cell hybrid obtained by fusinghuman embryonic 4172-positive
fibroblasts with a 4172-negative established murine cell line ;
100% of the cells ofthis hybrid, designated MRC-5 x CI ID,
displayed bright fluorescence. However, as shown in the right
column of Table I, all the fibroblastic cell lines derived from
adult donors were 4172 negative (Fig. 1 B) .
41`2 Antigen Expression on Neoplastic Cells
As it is well established that neoplastic cells may express
embryonic antigens, we investigated whether 4172 antigen
would be expressed by sarcoma-derived adulthuman cell line
or by adult fibroblasts transformed by SV40 . To this end, we
analyzed the 4172 expression on three SV40-transformed and
three sarcoma-derived adult cell lines . All the six neoplastic
lines analyzed displayed a strong reactivity (Fig. 1 C), while
the normal counterpart of SV40-transformed cell lines were
4172-negative . It is noteworthy that in the initial phases of
SV40 transformation, only a fraction of the cultured cells
expressed the 4172 antigen ; moreover, similar percentages of
cells expressed the nuclear viral T antigen as assessed by
indirect immunofluorescence. In addition, both 4172 and T
antigen showed a parallel increase during culture (data not
shown).
FIGURE 1
￿
Immunofluorescent staining of human fibroblasts, spared onto glass coverslips with the 4172 mAb . (A) Human embryonic
cells (ICIG-7) show a bright, dotted fluorescence on the cell membrane . On the contrary, (B) human adult fibroblasts (DUP/N)
are not stained . However, after SV40 transformation (DUP/N-SV40), they appear brightly stained by the 41`2 mAb (C) . x 800 .
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On plastic*
Onto fibrin*
FCR
Number of population doublings 96 h after seeding;
Effect of 4F2 mAb on Cell Surface-
related Functions
The growth of fibroblastic cells in vitro is dependent on
their ability to attach to surfaces, spread, contact, and move.
Since all of these processes are intimately connected with cell
division and are therefore likely to be controlled by cell surface
structures, we investigated the possible involvement of the
4172 antigen in these cell activities. Toward this end, we
analyzed the effect of 4172 mAb on (a) cell attachment and
spreading on different surfaces, (b) cellular contractility, which
was measured as FCR activity, and (c) growth rates of 4F2-
positive fibroblastic cells. In experiments designed to measure
the effect of 4172 mAb on cell spreading efficiency or FCR
activity, cells were detached by trypsin treatment and resus-
pended in Tyrode solution. Trypsin did not affect the 4172
antigen expression as assessed by indirect immunofluores-
cence(data not shown). As summarized in Table II, addition
of 4172 mAb did not affect the spreading efficiency nor the
FCR activity of both embryonic ICIG-7 fibroblasts and HT-
1080 fibrosarcoma cells; the observation of a reduced FCR
TABLE II
Effect of the Exposure to 41`2 Monoclonal Antibody
ICIG-7
Neoplastic
DUPN-SV40
HG-SV40
HU-EYE-SV40
HT-1080 Fibrosarcoma
TE-85 Osteosarcoma
RD Rabdomiosarcoma
ICIG-7 + 4F2
41`2 Binding
HT1080
￿
HT1080 + 4F2
30% 30%
4.5
￿
0.5
~ 5 h after seeding, cultures were fixed by addition of glutaraldehyde to growth medium (final concentration 5%). Thereafter 10 fields were scored at random
in three Petri dishes of each group for the degree of spreading and the number of spread cells. The spreading efficiency is expressed in arbitrary units ranging
from + to ++++.
Cells were initially seeded at 7 x 10° cells per Petri dish.
activity in sarcoma cells (as compared with normal cells) is in
agreement with previous reports (24, 25).
In another series of experiments, we studied the effect of
addition of saturating amounts of 4172 mAb on the growth
rates of different 4172-positive cell lines. It was found that 4172
mAb had no effect on the proliferation of ICIG-7, ICIG-7-
SV40, WI-38, VA-13, HG-SV40, and Te-85 cells, but had a
sharpinhibitory activity on the growth ofthe HT-1080 fibro-
sarcoma-derived cell line. A representative experiment is
shown in Fig. 2. Saturating amounts of 4172 mAb had no
effect on ICIG-7 (Fig. 2A), but sharply inhibited the prolifer-
ation ofHT-1080 cells(Fig. 2B). Similar results were obtained
in three additional experiments. The inhibitory effect of 4172
mAb on HT-1080 cell proliferation could not be simply
explained by a cytotoxic effect of the antibody for the follow-
ing reasons. First fetal bovine serum supplements were heat
inactivated; second, the mAb did not affect the growth of
other 4172-positive cell lines, nor did it have a cytotoxic effect
on monocytes or activated T and B cells in the absence of
complement; and finally, 90% HT-1080 cells, culture for 48
h in the presence of 4172 mAb, were viable, as assessed by
trypan blue exclusion test.
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Embryo fibroblasts
Binding of 41`2 mAb to
Embryo's age
TABLE I
Embryonic, Adult, or Malignant Human Fibroblastic
41`2 Binding Adult fibroblasts
Cells
Donor's age
Mo yr
IMR-90 Lung 4 Normal 52
964 Lung not known GLEN Bone-marrow 54
964 Skin not known HAL-14 Lung 52
ICIG-7 Lung 5 DUP-A Aponevrosis 30
WI-38 Lung 3 NS Skin 29
ICIG-8 Skin 4 MVL Skin 30
ICIG-9 Lung 4 AG 4151 Skin 59
MRC-5 Lung 31/2 AG 4353 Skin 70
MRC-5 x C11D (somatic AG4445 Skin 88
human x mouse) AG 4065 Skin 96
ICIG-7 SV40 AG 4055 Skin 29
VA-13 (WI-38 SV40) NMS-1 Skin 24
Al Skin 52
DUP-N Fibroma 17
Hu-EYE Neuroretina
HG Skin106
5
N 3
2
W d
105
o.7
w U
A.
ICIG 7
￿
11th P
B.
HT 1080 a1nP
1 2 3 4 1 2 3 4
DAYS IN CULTURE
￿
DAYS IN CULTURE
DISCUSSION
Our present studies show that the 4172 mAb originally raised
against human mononuclear cells (14-16) can be used to
identify transformed fibroblastic cells derived from adult do-
nors as well as normal fibroblasts at an early stage of devel-
opment. Moreover we provide evidence that the 4172 mAb
inhibits the growth ofa 4172-positive human fibrosarcoma cell
line. These data are of particular interest because no surface
markers have thus far been available that allow one to distin-
guish between embryonic and adult human fibroblasts. The
difference observed in 4172 antigen expression on cells at
different stages of differentiation may be important in view
of previous reports that suggested the existence of a relation-
ship between changes in the moieties of certain surface gly-
coproteins and growth decline in old versus young cell cultures
(27). It is likely that several surface molecules may be involved
in the functional activities of the cellsthemselves. For exam-
ple, it has been shown that mAbs specific for HLA-DR
molecules inhibited the interleukin-2-dependent proliferation
of human T cells and T cell clones (21). In addition, it has
been reported that 4172 mAb itself partially inhibited the
mitogenic response of T cells to phytohemagglutinin and
concanavalin A (14). Our present data suggest that 4172 surface
molecules are not involved in spreading and contractile activ-
ity of normal and tumoral fibroblasts, but they may play a
role in the growth regulation of human fibrosarcoma cells.
The differential effect of 4172 mAb on the growth of 4F2-
positive fibrosarcoma cells versus 4172-positive embryonic
fibroblasts could be related to the existence of different mo-
lecular forms ofthe 4172 antigen. In this context, Hemler and
Strominger recently demonstrated the existence of different
molecular forms of 4172 antigen on human T and B lympho-
blastoid cell lines (28). Thus, under reducing conditions, the
4172 antigen appeared to be composed of a sialylated heavy
subunit of 85,000 daltons on T cellsand 93,000 daltons on B
cells and of a light subunit of 41,000 daltons common to T
and B cells. According to preliminary data, HT 1080 fibro-
sarcoma cells express two types of heavy subunits, as assessed
by mono- and bidimensional gel electrophoresis; in contrast,
embryonic cells seem to express predominantly one type of
heavy chain (Azzarone, B., P. Eid, Y. Malpieces, H. Suarez,
and A. Fauci, manuscriptin preparation). It is of interest that
a cloned somatic hybrid obtained by fusing the 4172-positive
MRC-5 human embryonic lung fibroblastic cells with the
4172-negative C3H-C11D murine cells expressed the 4172 an-
tigen, although only few human chromosomes could be iden-
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FIGURE 2
￿
Semilog-
arithmic plots of cell
numbers in ICIG-7 (A)
and HT-1080 (13) cul-
tures exposed (O) or
not exposed (") to 4F2
monoclonal antibody.
tified in this hybrid (19). Our data are in agreement with a
recent report by Messer-Peters et al., who showed that the
4172 antigen maps to chromosome 11 (29).
Experiments are presently in progress to establish whether
SV40-induced transformation ofadult fibroblasts causes a de
novo expression of 4F2 antigen as previously shown for
human T cells following activation in mixed lymphocyte
culture (1, 14) or whether it only causes unmasking of an
internal antigenic determinant. In addition, we are presently
investigating whether differential effects on the growth rates
of different 4172-positive cell lines are associated with the
presence of different molecular forms of 4172 antigen. Hope-
fully, these studies will provide useful tools for a more accurate
dissection of the complex events associated with cellular dif-
ferentiation and/or transformation.
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